BMS finalizes sale of European facility
WuXi STA will take reigns of the operations, as CDMO expands
Bristol Myers Squibb (BMS) has officially completed the previously announced sale of its manufacturing facility in Couvet, Switzerland to WuXi STA, a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry.
As part of the deal, WuXi STA is acquiring the Couvet site’s operations and assets, which include the plant and equipment, as well as inheriting a technically experienced workforce.
The Couvet site is located in the canton of Neuchâtel, Switzerland. It is a state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
